The collision of thinking of big technical experts, the spark of wisdom ignites the audience

——Warmly congratulate the 2018 Ginkgo Leaf Dropping Pill Medical Research Enterprise Collaborative Innovation Alliance Annual Meeting

And the 2nd Wanbang Xinnuokang Ginkgo Biloba Product Research and Development Summit Forum was successfully held

On June 30, the 2018 Ginkgo Leaf Dropping Pill Medical Research Enterprise Collaborative Innovation Alliance Annual Meeting and the 2nd Wanbang Xinnuokang Ginkgo Leaf Product Research Co-sponsored by the School of Pharmacy of China Pharmaceutical University, the School of Pharmacy of Zhejiang University, and Wanbangde Pharmaceutical Group The Summit Forum on Development and Development was held in Wenling. 50 institutions including China Pharmaceutical University, Zhejiang University, Peking University, University of Sydney, China Academy of Chinese Medical Sciences, Beijing University of Traditional Chinese Medicine, Beijing Anzhen Hospital, West China Hospital of Sichuan University, Beijing Xiyuan Hospital, the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, etc. A number of experts from the alliance gathered together to summarize the relevant medical research results obtained by Wanbang Xinnuokang Ginkgo Biloba Dropping Pills since the establishment of the alliance one year ago, and to provide suggestions and wisdom for the future development of ginkgo biloba products.

At the meeting, Ye Xingfu, Deputy Director of Taizhou Market Supervision Administration, and Shen Nuo, Deputy Secretary-General of China Association of Traditional Chinese Medicine delivered speeches. The chairman of the alliance, Academician Wang Guangji, did not come to the scene due to physical reasons, but he still congratulated the successful convening of the alliance's annual meeting through a remote video, and made an important speech on the work of the alliance, "The establishment of the Ginkgo Leaf Dropping Pill Medical Research Enterprise Collaborative Innovation Alliance In line with the national trend of innovation and development of traditional Chinese medicine, its goal is to integrate international and domestic superior scientific research forces, carry out all-round integrated research from medicinal material extracts to preparation dripping pills, and strive to provide China and the world with sufficient evidence-based evidence and quality throughout the process. A new generation of high-quality ginkgo biloba products with controllable, stable and reliable efficacy, and high safety in combination medication.” He also hopes that the alliance will continue to develop into a benchmark for the development of industry-university-research cooperation in the traditional Chinese medicine industry, and promote the sustainable development of China’s traditional Chinese medicine industry.

Zhao Shouming, chairman of Wanbangde Group, expressed his sincere thanks to the experts and scholars who attended the forum. He pointed out that the current state supports the scientific research and technology development of traditional Chinese medicine. In order to seize the opportunity and innovate and develop, the alliance has achieved fruitful scientific research results since its establishment one year ago. In the next step, Wanbangde Pharmaceutical Group will continue to increase investment in scientific research and further conduct many valuable explorations on Ginkgo biloba. At the same time, improve the quality standards of traditional Chinese medicine, create a new generation of high-quality products, and promote the internationalization of Ginkgo biloba dripping pills.

At the meeting, Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director of Taizhou Market Supervision and Administration Bureau Ye Xingfu, and Peking University Professor Tu Pengfei also issued letters of appointment to new experts in the alliance.

Afterwards, relevant experts from the alliance made relevant thematic reports on Ginkgo Leaf Dropping Pills from four aspects: composition research, quality control, pharmacological mechanism, and clinical evidence-based, such as "Practice and Exploration of Intelligent Manufacturing of Ginkgo Leaf Dropping Pills", "Ginkgo Leaf Dropping Pills" Research on the Mechanism of Metabolism and Pharmacodynamic Action of Pills in Vitro and In vitro, "Research Plan of Ginkgo Leaf Dropping Pills for Optic Nerve Diseases", "Ginkgo Leaf Dropping Pills and Shuangxin Medicine - Based on the Discussion of Heart Failure Complicated with Depression", "Progress in Interpretation of Clinical Pathways" and cerebral infarction and other cardiovascular and cerebrovascular diseases recommended interpretation of Ginkgo biloba dripping pills. Experts at the meeting discussed the important role of ginkgo leaf dripping pills in coronary heart disease combined with diabetes, chronic heart failure, cerebral infarction and other cardiovascular and cerebrovascular diseases, optic neurodegenerative diseases and double heart medicine and other diseases and new medical fields. In-depth discussion and reach a consensus.

Ginkgo biloba dripping pill is an exclusive patented product in the country. It is included in the "Clinical Path Interpretation" compiled by the Ministry of Health with its unique advantages, and is a multi-disease (such as cerebral infarction, transient ischemic attack, stable coronary heart disease) , chronic stable angina pectoris interventional therapy, etc.) is the only recommended oral ginkgo biloba product, is the only recommended ginkgo biloba product in the "Chinese Expert Consensus on Diagnosis and Treatment of Cardiovascular Complicated Insomnia", and is the National Engineering Laboratory of the National Development and Reform Commission (the only clinical direction) and the National Ministry of Education. The key laboratory (natural drug active components and efficacy) key demonstration research products, is the first domestic pharmaceutical product collaborative innovation alliance of medical research enterprises - Ginkgo Leaf Dropping Pill Medical Research Enterprise Collaborative Innovation Alliance demonstration research product.

Academician Wang Guangji, chairman of the alliance, delivered a speech via remote video

Chairman Zhao Shouming delivering a speech

Professor Liu Meiyan from Beijing Anzhen Hospital gave a report entitled "Shuangxin Ginkgo Leaf Dropping Pills and Shuangxin Medicine Based on Heart Failure Complicated with Depression".

Professor Zeng Xiantao of Wuhan University made a report entitled "Analysis of Recommended Use of Ginkgo Leaf Dropping Pills Clinical Path Interpretation Related Diseases"

Report on "New Application of Ginkgo Leaf Dropping Pills in Blind Eye Diseases"

Wang Hong, Ph.D. of Zhejiang Pharmaceutical University, made a report on "Research on the In vivo Metabolism and Pharmacological Mechanism of Ginkgo Leaf Dropping Pills" report

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director of Taizhou Market Supervision and Administration Bureau Ye Xingfu, and Peking University Professor Tu Pengfei issued letters of appointment to the newly added experts of the alliance

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director of Taizhou Market Supervision and Administration Bureau Ye Xingfu, and Peking University Professor Tu Pengfei issued letters of appointment to the newly added experts of the alliance

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director of Taizhou Market Supervision and Administration Bureau Ye Xingfu, and Peking University Professor Tu Pengfei issued letters of appointment to the newly added experts of the alliance

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director of Taizhou Market Supervision and Administration Bureau Ye Xingfu, and Peking University Professor Tu Pengfei issued letters of appointment to the newly added experts of the alliance